Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn's disease and ulcerative colitis. The company's proprietary oral delivery platform generates potent antibodies that can be administered orally and are designed to maintain therapeutic activity throughout the human intestine. Its lead candidate, SOR102, simultaneously inhibits TNF-alpha and IL-23(p19), two clinically validated drivers of inflammatory bowel disease (IBD). In December 2024, Sorriso announced positive Phase 1b clinical trial results for SOR102 in ulcerative colitis, with data subsequently published in Lancet Gastroenterology & Hepatology and presented at ECCO 2025.